Berrie Center’s Magdalena Bogun, MD
Selected for NIH TrialNet Program for Emerging Leaders

Congratulations to  Magdalena Bogun, MD, adult endocrinologist at the Berrie Center, who was recently selected to participate in the newly established NIH Type 1 Diabetes TrialNet Emerging Leader Program. TrialNet is an international network of researchers who are exploring ways to prevent, delay and reverse the progression of type 1 diabetes (T1D).  The Berrie Center/Columbia University is one of the sites for this multi-center clinical study.  Robin Goland, MD, J. Merrill Eastman Professor and Berrie Center Co-Director, is the TrialNet Principal Investigator at the Berrie Center/Columbia site.

Dr. Bogun is one of only four physicians selected for this inaugural program designed, “to stimulate the engagement of new investigators in diabetes clinical research, with an initial emphasis on fostering the next generation of TrialNet clinical trial leaders.”  Each of the young investigators selected for this program are mentored by a senior TrialNet investigator; Dr. Bogun’s mentor is Dr. Goland.


test defualt

Dr. Bogun is excited to become part of the TrialNet Study team at the Berrie Center. She highlighted findings from the TrialNet Pathway to Prevention Study that helped establish the importance of antibody screening in relatives of people with T1D, screening that can diagnose T1D prior to symptoms or clinical illness.

Each Emerging Investigator, along with their mentor, and assistance from the TrialNet Emerging Investigator Committee, designed a research project utilizing existing TrialNet data. Dr. Bogun’s project is a longitudinal study of insulin secretion in the same subjects, who had metabolic testing both before and after diagnosis of T1D.  Says Dr. Bogun, “Understanding the patterns of insulin secretion would give us more understanding about the pathogenic evolution of the disease—which could in turn guide our treatments.”

Dr. Bogun came to the Berrie Center in July 2014 after completing a fellowship in endocrinology at the Yale University School of Medicine-New Haven Hospital.

“I am very excited I was selected,” said Dr. Bogun, who first became interested in endocrinology after college when she was a research assistant in a basic science laboratory at The Rockefeller University studying the development of estrogen receptors in the brain. “To do diabetes research and see patients is exactly the work I want to be doing, and there is no better place to do it than the Berrie Center,” where nearly half of her patients have T1D.

“I am very proud to be Dr. Bogun’s mentor in this important work,” said Dr. Goland. “I think this innovative program will help to foster the next generation of leaders in translational diabetes research.”